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Abstract
Background: Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies
and appears to arise mainly from transformation of pre-existing differentiated thyroid cancer
(DTC). However, the carcinogenic mechanism of anaplastic transformation remains unclear.
Previously, we investigated specific genes related to ATC based on gene expression profiling using
cDNA microarray analysis. One of these genes, transcription elongation factor A (SII)-like 4
(TCEAL4), encodes a member of the transcription elongation factor A (SII)-like gene family. The
detailed function of TCEAL4 has not been described nor has any association between this gene and
human cancers been reported previously.
Methods: To investigate the role of TCEAL4 in ATC carcinogenesis, we examined expression
levels of TCEAL4 in ACLs as well as in other types of thyroid cancers and normal human tissue.
Results: Expression of TCEAL4 was down-regulated in all 11 ACLs as compared to either normal
thyroid tissues or papillary and follicular thyroid cancerous tissues. TCEAL4  was expressed
ubiquitously in all normal human tissues tested.
Conclusion: To our knowledge, this is the first report of altered TCEAL4 expression in human
cancers. We suggest that loss of TCEAL4 expression might be associated with development of ATC
from DTC. Further functional studies are required.
Background
Anaplastic thyroid cancer (ATC) is one of the most lethal
tumors of all human malignancies [1-3]. ATC is well
known to often arise from transformation of differenti-
ated thyroid cancer (DTC) of the papillary or follicular
type [1-5]. However, little is known about the genetic
mechanisms of the transformation of DTC to ATC. We
have been attempting to identify new diagnostic markers
and drug-target molecules in ATC by cDNA microarray
technology, and lately have reported specific changes in
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expression of several genes in ATCs and cell lines derived
from anaplastic thyroid cancers (ACL)s [6].
In this paper, we describe a novel member of the group of
down-regulated genes that was identified by expression
profiling: transcription elongation factor A (SII)-like 4
(TCEAL4). NCBI accession number NM_024863, which is
located a Xq22.1. The coding sequence is 1077 basepairs
and the mRNA consists of 1516 basespairs according to
the NCBI "Gene" database (Gene ID 79921). TCEAL4
encodes a member of the transcription elongation factor
A (SII)-like (TCEAL) gene family. Members of this family
contain TFA domains and may work as nuclear phospho-
proteins that modulate transcription in a promoter con-
text-dependent manner [7-9]. To date, genetic alterations
of TCEAL4 in human cancers have not been described. In
this study, we examined expression levels of TCEAL4 in
anaplastic thyroid cancers as well as other types of thyroid
cancers and normal thyroid tissue. Expression of TCEAL4
was down-regulated in anaplastic thyroid cancers as com-
pared to either normal thyroid tissue or differentiated thy-
roid cancer tissue. Therefore, we attempted to clarify the
mechanism of down-regulation of TCEAL4 in ATC, lead-
ing to predictions about the function of this gene.
Methods
Primary thyroid tissue samples
Primary thyroid cancer tissues were obtained from
patients undergoing surgery. Normal thyroid- gland tis-
sues were collected from patients who received surgery for
papillary thyroid cancer at Ito Hospital, Tokyo. All
patients had given informed consent according to guide-
lines approved by the Institutional Research Board. Dis-
sected samples were frozen immediately after surgery and
stored at – 80°C until needed.
Cell lines
Eleven cell lines derived from human anaplastic thyroid
cancers were used for this study: 8305c, 8505c, ARO, FRO,
TTA1, TTA2, TTA3, KTA1, KTA2, KTA3, and KTA4. The cell
lines 8305c and 8505c were maintained in Dulbecco's
Modified Eagle Medium (Invitrogen, Carlsbad, CA, USA)
and ARO and FRO were maintained in Minimum Essen-
tial Medium (MEM). The other seven cell lines were
grown in RPMI 1640. Papillary thyroid cancer cells (NPA)
and follicular thyroid cancer cells (WRO) were cultured in
RPMI 1640. All media contained 10% fetal bovine serum
(FBS) without antibiotics. The cells were cultured in a
37°C incubator under 5 % CO2. In addition, to investi-
gate  TCEAL4  expression in other cancer cell lines, we
examined 91 cancer cell lines, including hepatic cell carci-
noma (SK-HEP-1, Hep G2, C-HC-4, Hep-KANO CL2,
Hep-TABATA, HuH7, HT17, Li-7, PLC/PRF/5, Hep38,
WRL68, Chang Liver, C3A) gastric cancers (HuGC-
OOHIRA, AZ521, H-111-TC, SH-10-TC, MKN-7, NUGC-
4), colon cancers (DLD-1, SW480, HCT-15, WiDr), pan-
creatic cancers (MIA Paca2, PK8), breast cancers (MDA-
MB-453, CRL1500, YMB-1-E, MCF7, and HBL100), ovar-
ian cancers (CAOV-3, SK-OV-3, OVCAR-3, OV-1063,
OVK18), cervical cancers (SIHA, HT-3, D98-AH2, Hela
TG, Hela, Ca Ski, Me-180, Hela.P3), lung cancers (RERF-
LC AI, PC-14, A549, EBC-1, LU65, LU99, LK-2), urinary
bladder cancers (5637, T24, EJ-1), renal cell carcinomas
(OS-RC-2, RCC10RGB, VMRC-RCW, Caki-1), bile duct
cancers (HuH-28, TFK-1), osteosarcomas (MG-63,
Saos02, HuO-3N1, U-2OS), neuroblastoma (IMR-32,
NH-12, SCCH-26, NB-1), glioblastomas, brain cancers
(TE671, U-138MG, U-373MG, U-118MG, KG-1-C, GI-1,
U251, SW1088, Daoy, DBTRG-05MG, D283 Med, A172,
T98G, u87MG, u251MG, SNB19, uw18, uw228).
RNA extraction and cDNA preparation
RNA was extracted as described previously [6]. Briefly,
thyroid tissues and cell lines that were collected by
trypsinization were homogenized with TRIZOL (Invitro-
gen, Carlsbad, CA, USA) following the manufacturer's
instructions. One microgram of extracted RNA was sepa-
rated by electrophoresis in 3.0 % formaldehyde denatur-
ing gels to assess RNA quality (RNA degradation).
Samples with the ratio of 28S/18S over 1.7 were selected
for densitometry. In brief, the intensity of each band was
evaluated with Alphaimager (AlphaInonotech, San Lean-
dro, CA, USA). RNA was purified using an RNeasy kit
(QIAGEN, Valencia, CA, USA) to eliminate DNA contam-
ination. cDNA was reverse-transcribed from 1 µg of total
RNA utilizing standard methodology.
Semi-quantitative-PCR (SQ-PCR)
To adjust the amount of transcribed cDNA, GAPDH was
selected as an internal control and SQ-PCR was performed
as previously described [6]. All primer sequences are
shown in Table 1. All primers were designed with Primer
3 after sequence information was obtained from NCBI
GenBank. Each SQ-PCR experiment was performed with 1
µl of cDNA as template, 5U of Takara EX Taq (Takara,
Otsu, Japan), 1 × PCR buffer (10 mM Tris-HCl, 50 mM
KCl, and 1.5 mM MgCl2), 10 nM dNTPs, and 10 pmol
each of the forward and reverse primers in a 30 µl total
reaction mixture. The PCR conditions 94°C for 2 minutes,
followed by, 94°C for 30 seconds, 60°C for 30 seconds,
and 72°C for 30 seconds for, 30 cycles in a Thermal Cycler
PT-200 (MJ Research Inc., Waltham, MA).
For the evaluation of gene expression between thyroid
cancers and normal thyroid -gland tissues, a 2.0% agarose
gel was used to separate 10 µl of SQ-PCR product, which
was visualized by ethidium bromide staining. The band
intensity for each sample was measured by AlphaImager
3300 (AlphaInonotech) after background subtraction. ABMC Cancer 2006, 6:260 http://www.biomedcentral.com/1471-2407/6/260
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16-bit imaging score was acquired from each sample. All
SQ-PCR experiments were done in duplicate.
Quantitative RT-PCR (Q-PCR)
Q-PCR experiments were performed with an ABI PRISM
7700 Sequence Detector (Applied Biosystems, Foster City,
CA, USA) according to the comparative threshold cycle
(Ct) method following manufacturer's protocol (SYBR
Premix Ex Taq™, TAKARA BIO INC., Otsu, Japan). Q-PCR
was performed in a 20 ul total reaction mixture in 96-well
plates containing; 2 ul of cDNA as template, 10 ul of
SYBER Green (Takara, Otsu, Japan), 0.4 ul of ROX dye
(Takara, Otsu, Japan), and 0.8 ul of 10 pmol each of the
forward and reverse primers. Thermal cycler conditions
were 95°C for 30 seconds, followed by, 95°C for 10 sec-
onds and 60°C for 30 seconds, repeated for 40 cycles. All
quantitative RT-PCR products were visualized on 2% aga-
rose gels to ensure single products. The A difference in
expression between normal thyroid- gland tissue and
sample X of an ACL is defined as follows:
∆CtX = Ct-TCEAL4X - Ct-GAPDHX
(Ct-TCEAL4, GAPDH are threshold cycles for amplification of
TCEAL4 and GAPDH, respectively)
∆CtN-ave = Sum of ∆CtN1 to ∆CtN5/5
(average of ∆Ct of five normal thyroid tissues)
∆∆CtX = ∆CtX - ∆CtN_ave
Expression ratio of TCEAL4  to normal thyroid tissue
(sample X/average of five normal thyroid tissues) = 2(-∆∆Ct
X)
Expression of TCEAL4 in normal human tissues
To confirm the expression status of TCEAL4 in human
organs containing thyroid tissue, we performed SQ-PCR
with Human MTC panel 1 & 2 (BD Bioscience, Palo Alto,
CA, USA), using SQ-PCR conditions described above.
Results
Expression of TCEAL4 in primary thyroid tissues
We examined the expression of TCEAL4 in 5 normal thy-
roid tissues, 5 PTCs, and 5 ATCs by SQ-PCR and Q-PCR.
Expression of TCEAL4 was significantly down-regulated in
ATCs as compared to normal thyroid tissues and PTCs
(Figure 1A and 1B). Clinical profiles of patients that had
samples subjected to SQ-PCR are shown in Table 2.
Down-regulation of TCEAL4 in ACLs
We also investigated the expression of TCEAL4 in cell lines
derived from 11 anaplastic thyroid cancers (ACLs) and
five normal thyroid tissues by SQ-PCR and Q-PCR.
Expression of TCEAL4 was markedly reduced in all ACLs
as compared to normal thyroid tissue (Figure 2A and 2B).
The expression ratio of GAPDH and TCEAL4 revealed that
TCEAL4 was significantly under-expressed in ACLs.
Expression of TCEAL4 in human cancer cell lines
To assess whether the loss of expression of TCEAL4 was
specific to ACLs, we examined TCEAL4 expression by SQ-
PCR in 91 of cancer cell lines including differentiated thy-
roid cancers derived from papillary and follicular cancers.
TCEAL4 expression was absent or under-expressed in 46
of 91 (51%) cell lines examined, namely hepatic cell car-
cinomas, gastric cancers, colon cancers, ACLs, ovarian
cancers, cervical cancers, lung cancers, urinary bladder
cancers, renal cell carcinomas and neuroblastomas. Inter-
estingly, expression of TCEAL4 was markedly reduced in
ACLs as compared to DTCs (Figure 3).
Expression of TCEAL4 in human normal tissues
We also examined expression of TCEAL4 by SQ-PCR in
normal human tissues including normal thyroid gland.
TCEAL4 was expressed ubiquitously in all normal human
tissues tested: heart, brain, placenta, lung, liver, skeletal
muscle, kidney, spleen, pancreas, thymus, prostate, testis,
ovary, small intestine, colon, leukocytes, and thyroid (Fig-
ure 4).
Discussions and conclusion
ATC has poor prognosis with a one year survival rate
whereas PTC has a favorable prognosis [1-3]. It is well
known that most ATCs arise from transformation of DTC
[1-5], especially PTCs with repeated recurrences in
regional lymph nodes [11]. Recently, molecular studies
have been developed to analyze ATC. Mutations of TP53
[14,15], beta-catenin [16], and BRAF [17] were detected at
a high frequency in ATC. In addition, bcl-2 [18], cyclin D1
[19], Y-box binding protein (YB-1) [20], peroxisome pro-
liferator-activated receptor-γ (PPAR-γ) [21], maspin [22],
and haemoglobin beta (HBB) [10] have been reported to
Table 1: Primers for semi-quantitative and quantitative RT-PCR
Gene Forward primer (5'-3') Reverse primer (5'-3')
GAPDH ggaaggtgaaggtcggagt tgggtggaatcatattggaa
TCEAL4 (semi-quantitative-PCR) ctggctcattacctcaaggagta agtggacacagctttcagaattg
TCEAL4 (quantitative-PCR) gaaaaggaggggaaatctcg ggctttctctcgtcttgtggBMC Cancer 2006, 6:260 http://www.biomedcentral.com/1471-2407/6/260
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play an important role in anaplastic transformation of
thyroid cancer. In a previous study, we found frequent
allelic losses at 1q, 9p, 11p, 11q, 17p, 19p and 22q in a
panel of 21 ATCs suggesting that the region around these
chromosome loci might harbor a tumor suppressor gene
for ATC [23].
cDNA microarray technology has been developed to ana-
lyze a large number of genes in a biological sample at the
same time. For the current study, we discovered genetic
alterlation related to ATC carcinogenesis [6], and focused
on TCEAL4 on the basis of cDNA microarray results. The
protein encoded by this gene contains one transcription
elongation factor A (TCEAL4), SII-related family motif.
Yeh and Shatkin identified a gene from a Hela cell library
encoding p21 that belongs to the SII family [7]. This gene
may function as a nuclear phosphoprotein that modulates
transcription in a promoter context-dependent manner.
(A) Decreased expression of TCEAL4 in ATCs as compared to normal thyroid tissues and PTCs as shown by SQ-PCR Figure 1
(A) Decreased expression of TCEAL4 in ATCs as compared to normal thyroid tissues and PTCs as shown by SQ-PCR. The lane designa-
tions are as follows: M, size markers; 1–5, normal thyroid samples, 6–10, primary papillary thyroid cancer samples, 11–15, primary ana-
plastic thyroid cancer samples. (B) Results of quantitative RT-PCR. The average expression level of TCEAL4 among five normal thyroid 
tissues was set at 1.00, then relative expression ratios were calculated between normal and cancerous tissues.
TCEAL4 expression in primary PTC &ATC Fig.1A
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Table 2: Clinical profile of patients selected for RT-PCR
No. Histotype age sex
1 normal thyroid tissue 25 F
2 normal thyroid tissue 44 F
3 normal thyroid tissue 38 F
4 normal thyroid tissue 23 F
5 normal thyroid tissue 36 F
6 papillary thyroid cancer 27 F
7 papillary thyroid cancer 23 F
8 papillary thyroid cancer 33 F
9 papillary thyroid cancer 53 F
10 papillary thyroid cancer 62 F
11 anaplastic thyroid cancer 64 M
12 anaplastic thyroid cancer 56 M
13 anaplastic thyroid cancer 53 M
14 anaplastic thyroid cancer 71 F
15 anaplastic thyroid cancer 68 MBMC Cancer 2006, 6:260 http://www.biomedcentral.com/1471-2407/6/260
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The Rous sarcoma virus long terminal repeat (RSV LTR)
promoter was decreased by p21 indicating that both the
zinc finger-like motif and the arginine/serine-rich region
of p21 are essential for inhibition of RSV LTR function [8].
It was reported that p21, or TCEAL1 was expressed in all
normal human tissues tested by northern blot analysis
and this gene is located at Xq22.1 [9]. Multiple family
members of TCEAL4  are located on chromosome X.
This study showed that mRNA expression of TCEAL4 was
under-expressed in ATCs and ACLs as compared to nor-
mal thyroid tissues and DTCs. Interestingly, TCEAL4 was
expressed ubiquitously in normal human tissues. Based
on these results, we suggest that loss of TCEAL4 expression
might be associated with development of ATC from DTC
or normal thyroid glands. Unfortunately, we could not
examine protein expression of TCEAL4 in thyroid tissues
because an antibody of TCEAL4  was not available.
Gene silencing is caused by several reasons, including
methylation of promoter region and loss of heterozygos-
ity (LOH). Methylation of DNA promoter region is one of
the mechanisms for silencing transcription and inactivat-
ing tumor suppressor genes. In this study, we were unable
to examine LOH because normal paired DNA samples
were unavailable. Instead, we investigated the methyla-
tion status of the promoter region of TCEAL4 for 11 ACLs
as described previously [10] and found that it was mainly
(A) Down-regulation of TCEAL4 in ACLs as compared to normal thyroid tissues as shown by SQ-PCR Figure 2
(A) Down-regulation of TCEAL4 in ACLs as compared to normal thyroid tissues as shown by SQ-PCR. The following are the 
lane designations: M, size marker; 1–5, normal thyroid; 6, 8305c; 7, 8505c; 8, ARO; 9, FRO; 10, TTA1; 11, TTA2; 12, TTA3; 13, 
KTA1; 14, KTA2; 15, KTA3; 16, KTA4. (B) Results of quantitative RT-PCR. TCEAL4 expression of normal thyroid is the average 
of five normal thyroid glands. When the expression of normal thyroid was settled as 1.00, the ratio represented relative 
expression of TCEAL4 in the sample.
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SQ-PCR analysis of the expression of TCEAL4 in 91 of cancer cell lines Figure 3
SQ-PCR analysis of the expression of TCEAL4 in 91 of cancer cell lines. The lanes are designated as: M, size marker; 1, SK-HEP-
1; 2, Hep G2; 3, C-HC-4; 4, Hep-KANO CL2; 5, Hep-TABATA; 6, HuH7; 7, HT17; 8, Li-7; 9, PLC/PRF/5; 10, Hep38; 11, 
WRL68; 12, Chang Liver; 13, C3A; 14, HuGC-OOHIRA; 15, AZ521; 16, H-111-TC; 17, SH-10-TC; 18, MKN-7; 19, NUGC-4; 
20, DLD-1; 21, SW480; 22, HCT-15; 23, WiDr; 24, MIA Paca2; 25, PK8; 26, MDA-MB-453; 27, CDL1500; 28, YMB-1-E; 29, 
MCF7; 30, HBL100; 31, WRO; 32, NPA; 33, ARO; 34, FRO; 35, 8505c; 36, 8305c; 37, CAOV-3; 38, SK-OV-3; 39, OVCAR-3; 
40, OV-1063; 41, OVK18; 42, SIHA; 43, HT-3; 44, D98-AH2; 45, Hela TG; 46, Hela; 47, Ca Ski; 48, Me-180; 49, Hela.P3; 50, 
RERF-LC AI; 51, PC-14; 52, A549; 53, EBC-1; 54, LU65; 55, LU99; 56, LK-2; 57, 5637; 58, T24; 59, EJ-1; 60, OS-RC-2; 61, 
RCC10RGB; 62, VMRC-RCW; 63, Caki-1; 64, HuH-28; 65, TFK-1; 66, MG-63; 67, Saos02; 68, HuO-3N1; 69, U-2OS; 70, IMR-
32; 71, NH-12; 72, SCCH-26; 73, NB-1; 74, TE671; 75, U-138MG; 76, U-373MG; 77, U-118MG; 78, KG-1-C; 79, GI-1; 80, 
U251; 81, SW1088; 82, Daoy; 83, DBTRG-05MG; 84, D283 Med; 85, A172; 86, T98G; 87, u87MG; 88, u251MG; 89, SNB19; 90, 
uw18; 91, uw228.
Fig.3 TCEAL4 Expression in 91 of Cancer Cell Lines
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hemi-methylated (the data was not shown). We suggest
that methylation may be one of the mechanisms for the
down-regulation of TCEAL4 in ATC and ACL.
In conclusion, this is the first study that describes of
altered TCEAL4 expression in human cancer. The results
suggest that loss of expression of TCEAL4 might play a
role in anaplastic thyroid cancers. To confirm whether the
activity of TCEAL4 would suppress cell survival in ATC,
further functional analyses are required.
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Expression of TCEAL4 in normal human tissues Figure 4
Expression of TCEAL4 in normal human tissues. The following are the lane designations: M, size marker; 1, heart; 2, brain; 3, pla-
centa; 4, lung; 5, liver; 6, skeletal muscle; 7, kidney; 8, spleen; 9, pancreas; 10, thymus; 11, prostate; 12, testis; 13, ovary; 14, 
small intestine; 15, colon; 16, leukocytes; 17, thyroid.
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